Figure 6
Correlations between the cytotoxic activites (SI %) for the indicated pairs of standard- and targeted cytotoxic drugs (bortezomib, sorafenib, sunitinib and rapamycin) in gastric cancer samples at concentrations selected to provide optimal activity variation. These concentrations were: bortezomib 0.08 μM; sorafenib and sunitinib 20 μM; standard drugs as in Figure 4. Abbeviations: r, the correlation coefficient; P, the level of statistical significance.